ozempic novo nordisk - Search News

News

Novo Nordisk, Ozempic

Ozempic maker Novo Nordisk has its worst day since Black Monday

Shares of Novo Nordisk skidded on Tuesday as the Danish drugmaker reduced its expectations on wildly popular drugs Ozempic and Wegovy.

3 Minute Breakdowns on MSN · 3h

novo nordisk stock analysis: ozempic, wegovy, and market share - august 2025

Is Novo Nordisk stock a buy? An analysis of $NVO, its weight loss drugs Ozempic and Wegovy, and market share competition with Eli Lilly in August 2025.

24/7 Wall St. · 3d

Ozempic Maker Novo Nordisk Is Plunging 20%. Time to Sell or Buy More?

Danish pharmaceutical giant Novo Nordisk (NYSE:NVO) is watching its stock plummet 20% in morning trading after slashing its full-year sales and profit outlook for the second time this year. The announcement,

Eli Lilly, Novo Nordisk Shares Rally

Investing.com India · 7m

Eli Lilly, Novo Nordisk Shares Rally As Trump Administration Reportedly Plans To Experiment Including Weight-loss Drugs Under Medicaid, Medicare

Reuters · 22h

US plans to test Medicare, Medicaid coverage for weight-loss drugs, Washington Post reports

The Trump administration is considering a five-year pilot program to cover weight-loss drugs under Medicare and Medicaid, the Washington Post reported on Friday, citing documents from the Centers for Medicare and Medicaid Services.

Yahoo · 14h

Medicaid, Medicare may cover weight loss drugs under new pilot program: report

Blockbuster weight loss drugs like Wegovy and Zepbound have surged in popularity, but high prices have left them out of reach for many obese Americans.

15hon MSN

Why Novo Nordisk Stock Imploded This Week

Shares of Novo Nordisk ( NVO 2.48%) are falling this week, down 33% as of 3:27 p.m. ET on Friday. The drop comes as the S&P ...

17hon MSN

Novo Nordisk stock posts worst week since 2021, but analysts see a bigger problem ahead

Novo Nordisk stock plunges 30% after forecast cut, CEO shakeup, and rising competition hit investor confidence.

Ozempic Maker’s Stock Plunges 20% After Profit Warning

Novo Nordisk slashed its financial forecasts as it struggled to fight off competition in the United States. It also named a ...

Novo Nordisk: Is This An Overreaction Or The End Of The GLP-1 Fairy Tale?

Novo Nordisk faces slowing demand, rising competition, and CEO transition. Learn about challenges impacting its growth and ...

16h

A Medicare experiment could change who gets Ozempic

A five-year experiment aims to open access to blockbuster GLP‑1 drugs for obesity, something advocates have pushed for years.

Opinion

1dOpinion

Novo Nordisk’s Weight Loss Lesson

Furious competition in GLP-1 drugs rebuts the anti-pharma crowd.

New tariffs could raise prices of Ozempic, Wegovy

Some of the most recognizable brand names that could be impacted by new tariffs include Ozempic and Wegovy, two injectable drugs that have grown popular in recent years for their abilities to ...

Novo Nordisk (NVO) Extends Fall on 3rd Day as Pessimistic Outlook Lingers

We recently published 10 Stocks Hit by Painful Plunge. Novo Nordisk A/S (NYSE:NVO) is one of the best-performing stocks on ...

Some results have been hidden because they may be inaccessible to you

Show inaccessible results